Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial.
Saved in:
| Title: | Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. |
|---|---|
| Authors: | Yang Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., He Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Fan Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China. zhqfan@bjmu.edu.cn., Chen X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Zhang C; Beijing Chao Yang Hospital, Breast Disease Department, Beijing, China., Jiang H; Beijing Chao Yang Hospital, Breast Disease Department, Beijing, China., Wang X; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China., Wang X; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China., Xie F; Peking University People's Hospital, Breast Cancer Center, Beijing, China., Wang S; Peking University People's Hospital, Breast Cancer Center, Beijing, China., Luo B; Beijing Tsinghua Changgeng Hospital, Breast Disease Department, Beijing, China., Kang H; Xuan Wu Hospital Capital Medical University, Breast Disease Department, Beijing, China., Wang T; 307 Hospital of PLA, Breast Cancer Department, Beijing, China., Jiang Z; 307 Hospital of PLA, Breast Cancer Department, Beijing, China., Yuan P; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China., Xu B; Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China., Xu L; Peking University First Hospital, Breast Cancer Center, Beijing, China., Liu Y; Peking University First Hospital, Breast Cancer Center, Beijing, China., Li J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Xie Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Wang T; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China., Ouyang T; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2023 Jul 24; Vol. 9 (1), pp. 62. Date of Electronic Publication: 2023 Jul 24. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-023-00567-6 |
